首款减肥GLP-1仿制药获批,压力给到减重巨头

新浪医药
Sep 04

美东时间2025年8月28日,FDA批准梯瓦制药(Teva Pharmaceuticals)生产利拉鲁肽注射液仿制药),这标志着首个用于减肥的GLP-1受体激动剂仿制药正式问世。此次梯瓦获批的 Saxenda 仿制药适应症与原研药一致,适用于慢性体重管理:包括肥胖或超重且伴有至少一种体重相关合并症的成人患者,以及 12 岁及以上、体重至少 60 公斤的肥胖儿童患者。此次获批,是梯瓦制药在利拉鲁肽...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10